Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438348 | 0.83 | KIF11 (0.61) | KIF11DGAT1 | |
| SCHEMBL5429388 | 0.83 | KIF11 (0.71) | KIF11CYP11B2CYP11B1FFAR1 | |
| SCHEMBL21116892 | 0.80 | KIF11 (0.76) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL3718585 | 0.80 | KIF11 (0.57) | KIF11CYP11B2 | |
| SCHEMBL28203779 | 0.79 | KIF11 (0.56) | KIF11CYP11B2CYP11B1FFAR1 | |
| SCHEMBL30131431 | 0.77 | IKBKB (0.61) | DGAT1 | |
| SCHEMBL13927718 | 0.77 | IKBKB (0.61) | DGAT1 | |
| SCHEMBL5424591 | 0.76 | KIF11 (0.62) | KIF11 | |
| SCHEMBL5428342 | 0.76 | KIF11 (0.74) | KIF11 | |
| SCHEMBL2920377 | 0.75 | DGAT1 (0.56) | KIF11DGAT1CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-15 | — | — | US | claimed |
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1778214-A2 | NOVEL BIPHENYL COMPOUNDS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020358-A2 | NOVEL BIPHENYL COMPOUNDS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | KIF5B, KIF5C, KIF5A | KIF11 8/4885DGAT1 4287/4885CYP11B2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.